NASDAQ:JRNY

Health·Medical Research·NASDAQ:JRNY·News·Pharmaceuticals

Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial

Journey Medical Corp shares fell 3.5% to $6.09 late Monday, trailing the SPDR S&P Biotech ETF’s 2.2% drop. The company last reported Q1 revenue up 21% to $16 million, with $6.3 million from rosacea drug Emrosi. Cash stood at $27.2 million as of March 31. The next investor event is the annual meeting on June 24.

June 2, 2026

Forrestania Resources Exceeds 1 Moz Gold Resource Mark with MacPhersons Update
June 1, 2026, 8:10 PM EDT. Forrestania Resources (ASX: FRS) has surpassed 1 million ounces in its global JORC Mineral Resource following an update at the MacPhersons deposit, now totaling 1,007,800 oz gold (Au) across 25.7 million tonnes at 1.22 g/t. The MacPhersons resource includes measured, indicated, and inferred categories, enhancing the Coolgardie Gold Hub. Recent drilling programs at Lady Lila, Mt Palmer, and Johnson Range projects have yielded significant high-grade gold intercepts, further strengthening the portfolio. Strategic acquisitions, including Midas Minerals and other WA tenements, expand Forrestania's footprint within the Southern Cross Greenstone Belt. The company is also advancing its Lake Johnston processing facility conversion from nickel to gold production, aiming to establish a central processing hub for its growing gold resources.